issues with glp 1 drugs GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH If GLP-1 Drugs Are Good

Glucagon-Like Peptide-1 Attenuates Endothelial Barrier Injury in Diabetes via cAMP/PKA Mediated Down-Regulation of MLC Phosphorylation

Studies and clinical trials have shown that people who take these medications may lose up to 15% of their body weight if combined with a healthy diet and exercise

Srivastava, G

Interestingly, some of them are able to cross the bloodbrain barrier and act on the brain to stimulate satiety [2], which leads to food intake reduction and, consequently, body weight loss, which occurs at the expense of fat mass

L.RoethD.SunL.HorriganF

GLP-1 drugs, formally called glucagon-like peptide-1 receptor agonists, are incretin-based therapies that activate the GLP-1 receptor